Summary
Various drugs are widely used in the prophylaxis and treatment of malaria. In the prevention of malaria in travellers, a careful risk-benefit analysis is required to balance the risk of acquiring potentially serious malaria against the risk of harm from the prophylactic agent. Unfortunately, the information needed to perform accurate analyses of this type is not available for most antimalarials.
In the prophylaxis of malaria, chloroquine and proguanil have an excellent safety record, being very rarely associated with severe adverse reactions in the recommended dosages. However, in many parts of the world they are no longer effective prophylactic agents. Pyrimethamine-dapsone (Maloprim®) is associated with agranulocytosis, especially if the recommended dose is exceeded, and should be reserved as a second-line agent for travellers to high risk areas. Pyrimethaminesulfadoxine (Fansidar®) and amodiaquine are associated with a relatively high incidence of potentially fatal reactions, and are no longer recommended for prophylaxis. Mefloquine, a relative newcomer, may provoke severe neuropsychiatric reactions with a frequency of 1 in 15 000 to 20 000 users at the prophylactic dosage.
In the treatment of Plasmodium falciparum malaria, which has a high mortality if untreated, a greater risk of adverse reactions to antimalarial drugs is acceptable. As chloroquine resistance has become widespread, alternative agents including quinine, mefloquine, pyrimethamine-sulfadoxine, tetracyclines, halofantrine and artemisinin (qinghaosu) and its derivatives may be used in treatment regimens. The therapeutic ratios for chloroquine, quinine and mefloquine are narrow and toxicity is frequent when recommended treatment dosages are exceeded; parenteral administration above the recommended dose range is especially associated with the hazards of cardiac and neurological toxicity.
Similar content being viewed by others
References
ABPI. Fansidar® data sheet. ABPI data sheet compendium, pp. 1245–1246, Datapharm Publications Limited, London, 1991–1992a
ABPI. Lariam® data sheet. ABPI data sheet compendium, pp. 1251–1252, Datapharm Publications Limited, London, 1991–1992b
Akinyanju O, Goddell JC, Ahmed I. Pyrimethamine poisoning. British Medical Journal 4: 147–148, 1973
Baker H. The influence of chloroquine and related drugs on psoriasis and keratoderma blenorrhagica. British Journal of Dermatology 78: 161–166, 1966
Barss P. Fatal dapsone agranulocytosis in a Melanesian. Leprosy Review 57: 63–66, 1986
Bateman DN, Dyson EH. Quinine toxicity. Adverse Drug Reactions and Accidental Poisoning Reviews 4: 215–233, 1986
Björkman A, Steffen R, Armengaud M, Picot N, Piccoli S. Malaria chemoprophylaxis with mefloquine. Lancet 337: 1479–1480, 1991
Boland MF, Brennand Roper SM, Henry JA. Complications of quinine poisoning. Lancet 1: 384–385, 1985
Boots M, Phillips M, Curtis JR. Megaloblastic anaemia and pancytopenia due to proguanil in patients with, chronic renal failure. Clinical Nephrology 18: 106–108, 1982
Bruce-Chwatt LJ. Three hundred years of the Peruvian fever bark. British Medical Journal 296: 1486–1487, 1988
Bruce-Chwatt LJ, Hutchinson DBA. Agranulocytosis associated with Maloprim. British Medical Journal 288: 65–66, 1984
Bryson HM, Goa KL. Halofantrine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs 43: 236–258, 1992
Cann HM, Verhulst HL. Fatal acute chloroquine poisoning in children. Pediatrics 27: 95–102, 1961
Carson PE, Hohl R, Nora MV, Parkhurst GW, Ahmad T, et al. Toxicology of the 8-aminoquinolines and genetic factors associated with their toxicity in man. Bulletin of the World Health Organization 59: 427–437, 1981
CDC 1985. Centers for Disease Control: revised recommendations for preventing malaria in travelers to areas with chloroquine-resistant P. falciparum. Morbidity and Mortality Weekly Report 34: 185–194, 1985
CDC 1990. Recommendations for the prevention of malaria among travelers (leads from the Morbidity and Mortality Weekly Report). Journal of the American Medical Association 263: 2729–2740, 1990
Chan TK, Todd D, Tso SC. Drug-induced haemolysis in glucose6-phosphate dehydrogenase deficiency. British Medical Journal 2: 1227–1229, 1976
Chongsuphajaisiddhi T. Malaria in paediatric practice. In Wernsdorfer & McGregor (Eds) Malaria: principles and practice of malariology, pp. 889–912, Churchill Livingstone, Edinburgh, 1988
Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizonticidal and gametocytocidal drug. Bulletin of the World Health Organization 59: 391–395, 1981
Collignon P, Hehir J, Mitchell D. Successful treatment of falciparum malaria in pregnancy with mefloquine. Lancet 1: 967, 1989
Cot M, Roisin A, Barro D, Yada A, Verhave J-P, et al. Effect of chloroquine chemoprophylaxis during pregnancy on birth-weight: results of a randomized trial. American Journal of Tropical Medicine and Hygiene 46: 21–27, 1992
Craven SA. Photosensitivity to pyrimethamine?. British Medical Journal 2: 556, 1974
Daniels AM. Mouth ulceration associated with proguanil. Lancet 1: 269, 1986
Davis TME, Supanaranond W, Pukrittayakamee S, Karbwang J, Molunto P, et al. A safe and effective consecutive-infusion regimen for rapid quinine loading in severe falciparum malaria. Journal of Infectious Diseases 161: 1305–1308, 1990
Degowin RL, Eppes RB, Powell RD, Carson PE. The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bulletin of the World Health Organization 35: 165–179, 1966
Dollery C, Boobis AR, Burley D, Davies DM, Davies DS, et al. (Eds) Therapeutic drugs, Churchill Livingstone. Edinburgh, 1991
Easterbrook M. Ocular effects and safety of antimalarials. American Journal of Medicine 85(suppl. 4A): 23–29, 1988
Editorial. Pyrimethamine combinations in pregnancy. Lancet 2: 1005–1007, 1983
Editorial. Childhood chloroquine poisonings — Wisconsin and Washington. Journal of the American Medical Association 260: 1361, 1988
Editorial. Halofantrine in the treatment of malaria. Lancet 2: 537–538, 1989
Editorial. Rediscovering wormwood — qinghaosu for malaria. Lancet 339: 649–651, 1992
Edstein MD, Veenendaal JR, Hyslop R. Excretion of mefloquine in human breast milk. Chemotherapy 34: 165–169, 1988
Fadat G, Le Bras J, Hengy C, Louis JP, Gimou MM, et al. Efficacy of amodiaquine against chloroquine-resistant malaria in Cameroon. Lancet 338: 1092, 1991
Ferone R. Dihydrofolate reductase inhibitors. In Peters & Richards (Eds) Antimalarial drugs II: current antimalarials and new drug developments, pp. 214–216, Springer-Verlag, Berlin, 1984
Fleming AF. Antimalarial prophylaxis in pregnant Nigerian women. Lancet 335: 45, 1990
Friman G, Nyström-Rosander, Jonsell G, Björkman A, Lekås G, et al. Agranulocytosis associated with malaria prophylaxis and Maloprim. British Medical Journal 286: 1244–1245, 1983
Gilks CF, Peto TEA. Doxyxycline prophylaxis in malaria. Lancet 1: 1487, 1987
Hall AP, Doberstyn EB, Karnchanchetanee C, Samransamruajkit S, Laixuthai B, et al. Sequential treatment with quinine and mefloquine or quinine and pyrimethamine-sulfadoxine for falciparum malaria. British Medical Journal 1: 1626–1630, 1977
Hanson SN, Kuylen K, Björkman AB. Hairloss and scaling with proguanil. Lancet 1: 225, 1989
Harpey JP, Darbois Y, Lefèbvre G. Teratogenicity of pyrimethamine. Lancet 2: 399, 1983
Harries AD, Forshaw AI, Friend HM. Malaria prophylaxis among British residents of Lilongwe and Kasungu districts, Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene 82: 690–692, 1988
Hart CW, Naunton RF. The ototoxicity of chloroquine phosphate. Archives of Otolaryngology 80: 407–412, 1964
Hatton CSR, Peto TEA, Bunch C, Pasvol G, Russell SJ, et al. Frequency of neutropenia associated with amodiaquine prophylaxis. Lancet 1: 411–414, 1986
Hellgren U, Rombo L, Berg B, Carlson J, Wiholm B-E. Adverse reactions to sulfadoxine-pyrimethamine in Swedish travellers: implications for prophylaxis. British Medical Journal 295: 365–366, 1987
Hernborg A. Stevens-Johnson syndrome after mass prophylaxis with sulfadoxine for cholera in Mozambique. Lancet 2: 1072–1073, 1985
Horton RJ, Parr SN, Baker LC. Clinical experience with halofantrine in the treatment of malaria. Drugs under Experimental and Clinical Research 16: 497–503, 1990
Jallon P. Use of mefloquine in epileptic patients. Journal of Neurology, Neurosurgery and Psychiatry 51: 732, 1988
Koch-Weser J. Quinidine-induced hypoprothrombinaemic haemorrhage in patients on chronic warfarin therapy. Annals of Internal Medicine 68: 511–517, 1968
Looareesuwan S, Phillips RE, White NJ, Kietinun S, Karbwang J, et al. Quinine and severe falciparum malaria in late pregnancy. Lancet 2: 4–8, 1985
Looareesuwan S, Viravan C, Vanijanonta S, Wilairatana P, Suntharasamai P, et al. Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria. Lancet 339: 821–824, 1992b
Looareesuwan S, Wilairatana P, Vanijanonta S, Kyle D, Webster K. Efficacy of quinine-tetracycline for acute uncomplicated falciparum malaria in Thailand. Lancet 339: 369, 1992a
Luxemburger C, Nosten F, ter Kuile F, Frejacques L, Chongsuphajaisiddhi T, et al. Mefloquine for multidrug-resistant malaria. Lancet 338: 1268, 1991
Luzzi GA, Warrell DA, Barnes AJ, Dunbar EM. Treatment of primaquine-resistant Plasmodium vivax malaria. Lancet 340: 310, 1992
McCann WP, Permisohn R, Palmisano PA. Fatal chloroquine poisoning in a child: experience with peritoneal dialysis. Pediatrics 55: 536–538, 1975
McCormack D, Morgan WKC. Fansidar hypersensitivity pneumonitis. British Journal of Diseases of the Chest 81: 194–196, 1987
MacKenzie AH. Ocular safety of huge cumulative antimalarial dosage. Arthritis and Rheumatism 24: 570, 1981
MacKenzie AH. Antimalarial drugs for rheumatoid arthritis. American Journal of Medicine 75(suppl. 6A): 48–58, 1983
Miller KD, Lobel HO, Satriale RF, Kwitsky JN, Stern R, et al. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. American Journal of Tropical Medicine and Hygiene 35: 451–458, 1986
Mukherjee S, Bhose LN. Induction of labor and abortion with quinine infusion. American Journal of Obstetrics and Gynecology 101: 853–854, 1968
Mulley G. Proguanil and mouth ulcers. Lancet 2: 177, 1974
Nathwani D, Currie PF, Douglas JG, Green ST, Smith NC. Plasmodium falciparum malaria in pregnancy: a review. British Journal of Obstetrics and Gynaecology 99: 118–121, 1992
Ognibene AJ. Agranulocytosis due to dapsone. Annals of Internal Medicine 72: 521–524, 1970
Olsen TG. Chloroquine and psoriasis. Annals of Internal Medicine 94: 546–547, 1981
Pang LW, Limsomwong N, Boudreau EF, Singharaj P. Doxycyc-line prophylaxis for falciparum malaria. Lancet 1: 1161–1164, 1987
Parke A. Antimalarial drugs and pregnancy. American Journal of Medicine 85(suppl. 4A): 30–33, 1988
Pasvol G, Newton CRJC, Winstanley PA, Watkins WW, Peshu NM, et al. Quinine treatment of severe falciparum malaria in African children: randomized comparison of three regimens. American Journal of Tropical Medicine and Hygiene 45: 702–713, 1991
Pedersen KE, Madsen JL, Klitgaard NA, Kjaer K, Hvidt S. Effect of quinine on plasma concentration and renal digoxin clearance. Acta Medica Scandinavica 218: 229–232, 1985
Percival SPB, Meanock I. Chloroquine: ophthalmological safety and clinical assessment in rheumatoid arthritis. British Medical Journal 3: 579–584, 1968
Peters W. Drug resistance in malaria — a perspective. Transactions of the Royal Society of Tropical Medicine and Hygiene 63: 25–40, 1969
Peters W. Primaquine and other 8-aminoquinolines. In Peters & Richards (Eds) Antimalarial drugs I: history and current status of drug resistance, pp. 437–445, Springer-Verlag, Berlin, 1984
Peters W. Chemotherapy and drug resistance in malaria, Academic Press, London, 1987
Peto TEA. Toxicity of antimalarial drugs. Journal of the Royal Society of Medicine 82: 30–34, 1989
Peto TEA, Gilks CF. Strategies for the prevention of malaria in travellers: comparison of drug regimens by means of risk-benefit analysis. Lancet 1: 1256–1260, 1986
Phillips RE, Warrell DA, White NJ, Looareesuwan S, Karbwang J. Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. New England Journal of Medicine 312: 1273–1278, 1985
Phillips-Howard PA, Behrens RH, Dunlop J. Stevens-Johnson syndrome due to pyrimethamine/sulfadoxine during presumptive self-therapy of malaria. Lancet 2: 803, 1989
Phillips-Howard PA, West LJ. Serious adverse reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. Journal of the Royal Society of Medicine 83: 82–85, 1990
Rieckmann KH. Tetracycline prophylaxis in malaria. Lancet 2: 507, 1987
Riou B, Barriot P, Rimailho A, Band FJ. Treatment of severe chloroquine poisoning. New England Journal of Medicine 316: 1–6, 1988
Salako LA, Sowunmi A, Walker O. Evaluation of the clinical efficacy and safety of halofantrine in falciparum malaria in Ibadan, Nigeria. Transactions of the Royal Society of Tropical Medicine and Hygiene 84: 644–647, 1990
Sanders SW, Zone JJ, Foltz RL, Tolman RG, Rollins DE. Haemolytic anaemia induced by dapsone through breast milk. Annals of Internal Medicine 95: 465–466, 1982
Schwatrz DE, Eckert G, Hartmann D, Weber B, Richard-Lenoble D, et al. Single dose kinetics of mefloquine in man. Chemotherapy 28: 70–84, 1982
Silamut K, White NJ, Looareesuwan S, Warrell DA. Binding of quinine to plasma proteins in falciparum malaria. American Journal of Tropical Medicine and Hygiene 24: 681–686, 1985
Sirsat AM, Lalitha US, Pandya SS. Dapsone neuropathy — report of three cases and pathologic features of a motor nerve. International Journal of Leprosy 55: 23–29, 1987
Slutsker LM, Khoromana CO, Payne D, Allen CR, Wirima JJ, et al. Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. Bulletin of the World Health Organization 68: 53–59, 1990
SmithKline & French Laboratories. Halfan® data sheet, Welwyn Garden City, 1992
Spencer HC, Poulter NR, Lury JD, Poulter CJ. Chloroquine-as-sociated pruritus in a European. British Medical Journal 285: 1703–1704, 1982
Steffen RS, Somaini B. Severe cutaneous reactions to sulfadoxine/pyrimethamine in Switzerland. Lancet 1: 610, 1986
Stürchler D, Handschin J, Kaiser D, Kerr L, Mittelholzer ML, et al. Neuropsychiatric side-effects of mefloquine. New England Journal of Medicine 322: 1752–1753, 1990
Sowunmi A, Walker O, Salako LA. Pruritus and antimalarial drugs in Africans. Lancet 2: 213, 1989
Svanbom M, Rombo L, Gustaffson L. Unusual pulmonary reaction during short term prophylaxis with pyrimethamine-sulfadoxine (Fansidar). British Medical Journal 288: 1876, 1984
Sweeney TR. Drugs with quinine-like action. In Peters & Richards (Eds) Antimalarial drugs II: current antimalarials and new drug developments, pp. 275–287, Springer-Verlag, Berlin, 1984
Tanenbaum L, Tuffanelli DL. Antimalarial agents: chloroquine, hydroxychloroquine and quinacrine. Archives of Dermatology 116: 587–591, 1980
Ullsberg S, Lindqwist NG, Sjöstrand SE. Accumulation of chorioretinotoxic drugs in the foetal eye. Nature 227: 1257–1258, 1970
Voorhoeve HW, Meuwissen JHET. A case of pyrimethamine intoxication in a Papuan child. Tropical and Geographical Medicine 15: 82–85, 1963
Waldinger TP, Siegle RJ, Weber W, Voorhees JJ. Dapsone-induced peripheral neuropathy: case report and review. Archives of Dermatology 120: 356–359, 1984
Wanwimolruk S, Sunbhanich P, Pongmarutai M, Patamasucon P. Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. British Journal of Clinical Pharmacology 22: 346–350, 1986
Watt G, Shanks GD. Pyrimethamine/sulfadoxine for falciparum malaria. Lancet 338: 700–701, 1991
Webster LT. Drugs used in the chemotherapy of protozoal infections: malaria. In Goodman & Gilman (Eds) The pharmacacological basis of therapeutics, 7th ed., pp. 1029–1048, Macmillan, New York, 1985
Weinke T, Trautmann M, Held T, Weber G, Eichenlaub D, et al. Neuropsychiatric side effects after the use of mefloquine. American Journal of Tropical Medicine and Hygiene 45: 86–91, 1991
White NJ. Treatment and prophylaxis of falciparum malaria. Journal of Antimicrobial Chemotherapy 26: 728–729, 1990
White NJ, Miller KD, Churchill FC, Berry C, Brown J, et al. Chloroquine treatment of severe malaria in children: pharmacokinetics, toxicity and new dosage recommendations. New England Journal of Medicine 319: 1493–1500, 1988
White NJ, Waller D, Crawley J, Nosten F, Chapman D, et al. Comparison of artemether and chloroquine for severe malaria in Gambian children. Lancet 339: 317–321, 1992
White NJ, Warrell DA. The management of severe malaria. In Wernsdorfer & McGregor (Eds) Malaria: principles and practice of malariology, pp. 865–888, Churchill Livingstone, Edinburgh, 1988
White NJ, Warrell DA, Chanthavanich P, Looareesuwan S, Warrell MJ, et al. Severe hypoglycemia and hyperinsulinemia in falciparum malaria. New England Journal of Medicine 309: 61–66, 1983
White NJ, Watt G, Bergquist Y, Njelesani EK. Parenteral chloroquine for treating falciparum malaria. Journal of Infectious Diseases 155: 192–201, 1987
Wolfe MS, Cordero JF. Safety of chloroquine in chemosuppression of malaria during pregnancy. British Medical Journal 290: 1466–1467, 1985
Zitelli BJ, Alexander J, Taylor S, Kirk D, Miller MD, et al. Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar). Annals of Internal Medicine 106: 393–395, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Luzzi, G.A., Peto, T.E.A. Adverse Effects of Antimalarials. Drug-Safety 8, 295–311 (1993). https://doi.org/10.2165/00002018-199308040-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199308040-00004